iX Biopharma Ltd. Fundamental Analysis (SES: 42C.SI)
iX Biopharma Ltd. Fundamental Analysis (SES: 42C.SI)
iX Biopharma Ltd. (SES: 42C.SI) shows weak financial fundamentals with a PE ratio of -63.43, profit margin of -85.19%, and ROE of -2.14%. The company generates $0.0B in annual revenue with weak year-over-year growth of -11.77%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -280.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 42C.SI's fundamental strength across five key dimensions:
Efficiency Score
Weak42C.SI struggles to generate sufficient returns from assets.
Valuation Score
Excellent42C.SI trades at attractive valuation levels.
Growth Score
Moderate42C.SI shows steady but slowing expansion.
Financial Health Score
Moderate42C.SI shows balanced financial health with some risks.
Profitability Score
Weak42C.SI struggles to sustain strong margins.
Key Financial Metrics
Is 42C.SI Expensive or Cheap?
P/E Ratio
42C.SI trades at -63.43 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 42C.SI's PEG of -1.42 indicates potential undervaluation.
Price to Book
The market values iX Biopharma Ltd. at 101.82 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -151.93 times EBITDA. This is generally considered low.
How Well Does 42C.SI Make Money?
Net Profit Margin
For every $100 in sales, iX Biopharma Ltd. keeps $-85.19 as profit after all expenses.
Operating Margin
Core operations generate -80.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.14 in profit for every $100 of shareholder equity.
ROA
iX Biopharma Ltd. generates $-30.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
iX Biopharma Ltd. generates limited operating cash flow of $-5.21M, signaling weaker underlying cash strength.
Free Cash Flow
iX Biopharma Ltd. generates weak or negative free cash flow of $-5.33M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
42C.SI converts -1.04% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-63.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.42
vs 25 benchmark
P/B Ratio
Price to book value ratio
101.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
82.34
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.63
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-2.14
vs 25 benchmark
ROA
Return on assets percentage
-0.30
vs 25 benchmark
ROCE
Return on capital employed
-0.58
vs 25 benchmark
How 42C.SI Stacks Against Its Sector Peers
| Metric | 42C.SI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -63.43 | 32.14 | Better (Cheaper) |
| ROE | -213.69% | 550.00% | Weak |
| Net Margin | -85.19% | 30133.00% | Weak |
| Debt/Equity | 1.63 | 0.56 | Weak (High Leverage) |
| Current Ratio | 1.05 | 5.70 | Neutral |
| ROA | -30.26% | 3.00% | Weak |
42C.SI outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews iX Biopharma Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
181.59%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
30.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
31.69%
Industry Style: Defensive, Growth, Innovation
High Growth